EW - Earnings announcements

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to 11% from 8% to 10% Raising FY 2026 adjusted2 EPS guidance midpoint; new range of $2.95 to $3.05 from $2.90 to $3.05 Renewed clinical focus on proactive disease management with differentiated SAPIEN TAVR Compl

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and heal

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an

Innovation with Purpose, Powered by Science, Centered on Patients: Edwards' Commitment to Drive Value for the Healthcare Ecosystem Edwards Lifesciences (NYSE:EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure. "As we enter 202

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of $0.67 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling long-term outcomes equivalent to surgery at 7 years, further supported by 10-year follow-up of PARTNER 2 studies New ESC/EACTS guidelines simplify care pathways for all severe AS patients EVOQUE real-world da

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinici

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomatic patients in U.S. and now in Europe EuroPCR data confirm clinical and economic advantages of timely treatment for severe AS patients 10-year data from PARTNER II study confirm long-term outcomes and durability

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 Continuing to expect mid-year asymp

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicia

Edwards Lifesciences Corporation (NYSE:EW) will discuss the company's focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), the continued long-term performance of Surgical, and future opportunities with Structural Heart Failure and Aortic Regurgitation (AR). Highlights of today's conference include: Reaffirming original 2

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enrollment in CLASP IITR trial for PASCAL tricuspid First implants in the JOURNEY pivotal trial with the Edwards J-Valve AR system Rei

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024 Positive EVOQUE introduction with excellent patient outcomes; NCD process on track Critical Care sale expected to close late Q3 2024 Expect full-year 2024 Edwards sales growth of 8 to 10%; lowering TAVR guidance to 5 to 7% from 8 to 10%; increasing TMT

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives t

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT and Surgical; confident in TAVR guidance Critical Care spin-off on track; raising 2024 sales guidance "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategi

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives

Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying moderate AS patients Received early FDA approval for EVOQUE; ongoing European launch of EVOQUE Executed $400 million accelerated share repurchase in Q4; $867 million repurchased in 2023 Confident in 2024 gui

Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing l

Edwards Lifesciences Corporation (NYSE:EW) will discuss the company's sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference. Highlights of today's conference include: Expecting early completion of enrollment in PROGRESS, studying moderate AS patients, in early 2024 Expecting data from EARLY TAVR, studying severe asymptomatic AS patients, at TCT 2024 Commercializing EVOQUE tricuspid valve in Europe; expecting U.S. approval mid-2024 Expecting CE Mark for SAPIEN M3 by the end of 2025 Reaffirming 2023 financial guidance Projecting 2024 global sales of $6.3 -

IRVINE, Calif., July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion; constant currency1 sales grew 12 percentAll product groups achieved double digit constant currency sales growth in Q2Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percentQ2 EPS of $0.50 (includes charge from previous IP agreement); adjusted1 EPS of $0.66Encouraging data from Edwards' Benchmark Registry at the EuroPCR medical congressNew 2023 constant c

IRVINE, Calif., July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26, 2023, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-focused

IRVINE, Calif., April 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion; constant currency1 sales grew 13 percentQ1 TAVR sales grew 8 percent; constant currency sales grew 11 percentQ1 EPS of $0.56; adjusted1 EPS of $0.62Repurchased approximately $250 million of Edwards stock in Q1Completed enrollment of the transcatheter tricuspid valve replacement pivotal trialInitiated launch of the SAPIEN 3 Ultra RESILIA valve in Japan late last month

IRVINE, Calif., April 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2023 after the market closes on Wednesday, April 26, 2023, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-focus

IRVINE, Calif., Jan. 31, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook Q4 sales grew 1 percent to $1.35 billion; constant currency1 sales grew 7 percentQ4 TAVR sales were flat; constant currency sales grew 5 percentQ4 EPS of $0.65; adjusted1 EPS increased 25 percent to $0.642022 sales of $5.38 billion grew 3 percent; constant currency sales grew 8 percent2022 EPS of $2.44; adjusted1 EPS increased 12 percent to $2.48Meaningful progress on 8 pivotal trials across TAVR and TMTTR

IRVINE, Calif., Jan. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2022 after the market closes on Tuesday, January 31, 2023, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-fo

IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today's conference include: Global market opportunity across 4 product groups projected to double to nearly $20 billion by 2028Reaffirming October 2022 financial guidanceProjecting 2023 global sales of $5.6 - $6.0 billion; underlying growth of 9% - 12%Projecting 2023 TAVR sales of $3.6 - $4.0 bil

IRVINE, Calif., Oct. 27, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights and Outlook Q3 sales of $1.32 billion grew 1 percent; constant currency1 sales grew 7 percentQ3 TAVR sales grew 1 percent; constant currency sales grew 6 percentQ3 EPS of $0.55; adjusted1 EPS increased 13 percent to $0.61Recently discontinued surgical HARPOON program resulted in a net $0.07 per share charge2022 adjusted EPS guidance revised: $2.40 to $2.50, compared to 2021 adjusted EPS of $2.22Received

IRVINE, Calif., Oct. 20, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2022 after the market closes on Thursday, October 27, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-f

IRVINE, Calif., July 28, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights and Outlook Q2 sales of $1.37 billion were flat versus an elevated prior year; underlying1 sales grew 5 percentQ2 TAVR sales grew 1 percent; underlying 5 percentQ2 EPS was $0.65; adjusted1 EPS was $0.63Lowered second half underlying sales growth outlook to approximately 10 percentExpect strong double-digit adjusted EPS growth in the second halfRepurchased $355 million of stock in Q2"We continue to expect me

IRVINE, Calif., July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedica

IRVINE, Calif., April 26, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights and Outlook Q1 sales grew 10 percent to $1.34 billion; underlying1 13 percentQ1 TAVR sales grew 11 percent; underlying 14 percentQ1 EPS was $0.59; adjusted1 EPS was $0.60Full year 2022 financial guidance unchangedSurgical mitral tissue valve MITRIS RESILIA approved in the U.S.Repurchased approximately $400 million of stock in Q1"We were pleased with our first quarter results despite the pronounced impact t

IRVINE, Calif., April 19, 2022  /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2022 after the market closes on Tuesday, April 26, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-focuse

IRVINE, Calif., Jan. 26, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended December 31, 2021. Fourth Quarter Highlights and Outlook 2021 sales grew 19 percent, or 18 percent on an underlying1 basis Q4 sales grew 12 percent to $1.33 billion; underlying 13 percent Q4 TAVR sales grew 12 percent; underlying 13 percent Q4 EPS was $0.53; adjusted1 EPS was $0.51 Full year 2022 financial guidance unchanged Completed enrollment in CLASP IID and EARLY TAVR pivotal trials Received FDA approval for SAPIEN 3 with Alterra for pulmoni

IRVINE, Calif., Jan. 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, January 26, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-

IRVINE, Calif., Dec. 8, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today's conference include: Reaffirming October 2021 financial guidance Projecting 2022 global sales of $5.5 - $6.0 billion; underlying growth in the low double-digits Projecting 2022 TAVR sales of $3.7 - $4.0 billion; underlying growth 12-15% Projecting 2022 TMTT sales of $140 - $170 million Est

IRVINE, Calif., Oct. 27, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended September 30, 2021.  Third Quarter Highlights and 2021 Outlook Sales grew 15 percent to $1.3 billion; underlying1 sales grew 14 percent TAVR sales grew 15 percent; underlying 14 percent U.S. TAVR sales grew 12 percent; OUS approximately 20 percent Full year 2021 sales guidance range unchanged Q3 EPS was $0.54; full year EPS guidance remains unchanged Continued progress on five pivotal trials in TMTT"Third quarter sales increased 15 percent versu

IRVINE, Calif., Oct. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2021 after the market closes on Wednesday, October 27, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient

IRVINE, Calif., July 29, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2021.  Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent EPS was $0.78; adjusted1 EPS was $0.64 Continued progress on five pivotal trials in TMTT 2021 sales guidance raised to $5.2 to $5.4 billion from $4.9 to $5.3 billion 2021 adjusted EPS guidance raised to the high end

IRVINE, Calif., July 22, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2021 after the market closes on Thursday, July 29, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893.  For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13720547.  The call will also be available via live or archived webcast on the